Access the full text.
Sign up today, get DeepDyve free for 14 days.
A. Lieberman, A. Goodgold, S. Jonas, M. Leibowitz (1975)
Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone in Parkinson's diseaseNeurology, 25
Jaffe ME (1973)
Treatment of Parkinsonism— The Role of Dopa Decarboxylase Inhibitors, 2
T. Chase, A. Watanabe (1972)
Methyldopahydrazine as an adjunct to L‐dopa therapy in parkinsonismNeurology, 22
D. Calne, J. Reid, S. Vakil, S. Rao, A. Petrie, C. Pallis, J. Gawler, P. Thomas, Andrew Hilson (1971)
Idiopathic Parkinsonism Treated with an Extracerebral Decarboxylase Inhibitor in Combination with LevodopaBritish Medical Journal, 3
M. Yahr, R. Duvoisin, M. Mendoza, M. Schear, R. Barrett (1971)
Modification of L-dopa therapy of Parkinsonism by alpha-methyldopa hydrazine (MK-486).Transactions of the American Neurological Association, 96
C. Markham, S. Diamond, L. Treciokas (1974)
Carbidopa in Parkinson disease and in nausea and vomiting of levodopa.Archives of neurology, 31 2
M. Leibowitz, Abraham Lieberman (1975)
Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone on the cardiovascular system of patients with Parkinson's diseaseNeurology, 25
P. Papavasiliou, G. Cotzias, S. Düby, A. Steck, C. Fehling, M. Bell (1972)
Levodopa in Parkinsonism: potentiation of central effects with a peripheral inhibitor.The New England journal of medicine, 286 1
C. Marsden, J. Parkes, J. Rees (1973)
A year's comparison of treatment of patients with parkinson's disease with levodopa combined with carbidopa versus treatment with levodopa alone.Lancet, 2 7844
Yahr MD Hoehn MM (1967)
Parkinsonism: Onset, progression, and mortalityNeurology, 17
D. Paty, N. Jaatoul, A. Kertesz, W. Mcinnis (1975)
Alpha Methyldopahydrazine as an Adjunct to Levodopa Therapy in Parkinson’s DiseaseCanadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 2
Abstract • Twenty-one patients with Parkinson's disease were studied because their low maintenance dosages of carbidopa-levodopa in the customary ratio of 1:10 provided less than the daily 75 mg of carbidopa believed nescessary to achievo full inhibition of extracerebral dopa decerboxylation. The dosage of carbidopa was increassd 2.5 times to between 75 and 150 mg daily, while the mean dosage of levodopa essentially was unchanged. The new carbidopa-levodopa ratio was 1:4. During 15 months, this treatment produced a moderate decrease in the severity of parkinsonism and a marked decrease in paripheral adverse reactions, without a significant increase in the central adverse effects of levodopa. It is concluded that increasing the dosage of carbidopa may be beneficial to patients with Parkinson's disease receiving less than 75 mg of carbidopa and 750 mg of levodopa daily. References 1. Jaffe ME: Clinical studies of carbidopa and L-Dopa in the treatment of Parkinson's disease , in Yahr MD (ed): Treatment of Parkinsonism— The Role of Dopa Decarboxylase Inhibitors . New York, Raven Press, 1973, vol 2, pp 161-172. 2. Papavasiliou PS, Cotzias GC, Düby SE, et al: Levodopa in Parkinsonism: Potentiation of central effects with a peripheral inhibitor . N Engl J Med 286:8-14, 1972.Crossref 3. Yahr MD, Duvoisin RC, Mendoza MR, et al: Modification of L-dopa therapy of parkinsonism by α-methyldopa hydrazine (MK-486) . Trans Am Neurol Assoc 96:55-58, 1971. 4. Markham CH, Diamond SG, Treciokas LJ: Carbidopa in Parkinson's disease and in nausea and vomiting of levodopa . Arch Neurol 31:128-133, 1974.Crossref 5. Marsden CD, Parkes JD, Rees JE: A year's comparison of treatment of patients with Parkinson's disease with levodopa combined with carbidopa versus treatment with levodopa alone . Lancet 2:1459-1462, 1973.Crossref 6. Chase TN, Watanabe AM: Methyldopa hydrazine as an adjunct to L-dopa therapy in parkinsonism . Neurology 22:384-392, 1972.Crossref 7. Hoehn MM, Yahr MD: Parkinsonism: Onset, progression, and mortality . Neurology 17:427-442, 1967.Crossref 8. Lieberman A, Goodgold A, Jonas S, et al: Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone in Parkinson's disease . Neurology 25:911-916, 1975.Crossref 9. Paty DW, Jaatoul N, Kertesz A, et al: Alpha methyldopahydrazine as an adjunct to levodopa therapy in Parkinson's disease . Can J Neurol Sci 2:169-172, 1975. 10. Calne DB, Reid JL, Vaket SD, et al: Idiopathic Parkinsonism treated with an extracerebral decarboxylase inhibitor in combination with levodopa . Br Med J 3:729-732, 1971.Crossref 11. Liebowitz M, Lieberman A: Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone on the cardiovascular system of patients with Parkinson's disease . Neurology 25:917-921, 1975.Crossref
Archives of Neurology – American Medical Association
Published: Mar 1, 1980
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.